Poolbeg Pharma Share Price (POLB)

Agreed pretty clueless

Here's an example of how prolific their writers are expected to be. The observant will spot a few glaring errors in Boyrazian's analysis/understanding of ORPH, most here understand better.

How much research do you imagine these guys do before hitting the keyboard? A few minutes is my guess.

https://www.fool.co.uk/author/tmfboyrazian/

Ref Motelyfool,

They repeat the same errors as they did with ORPH. They can't even grasp the basics, this being POLB does not take anything through to phase III, they pass the baton on to big pharma.

The other issue with MF, is there freelance writers are asked to write about 3-4 companies in each editorial, with c 200 words each. I know because I was asked by Tom Blake if I would be interested in contributing to MF. I declined because their writers are nothing more than clickbait fodder. There is no way I am writing fluff pieces for clickbait.

MF was once a great resource for investors. Sadly, they backed away from the UK to focus on the US market. They have adopted a clickbait policy now aimed at reeling in subscriptions with poorly research editorials.

Hi Elric, I hope you’re doing well! It’s nice to connect with you. My name is Tom Blake and I came across your website and Substack recently, it looks like you’re covering some very interesting companies! Our team is always looking to collaborate with new industry and company experts, and I'd love the opportunity to learn more about you and discuss a potential partnership with The Motley Fool. Specifically, we're looking for industry and company experts to join the team on a contractor basis to share their insights with our growing community of Fool investors. If you're interested, I'm happy to send over additional information via email! Thanks, and all the best! Tom

https://youtu.be/mtvecVjrHyg

Don't know why this keeps springing to mind

Thanks Greend100. I readily admitted the distinguishing terminology can be confusing so I'm not surprised if a general financial markets journo has got things mixed up. Yours is a very specialist field wherein even many ORPH LTH's struggle. He may welcome a question from you re his source as an opportunity to learn more himself.

I also said some people criticise The Motley Fool but that I was open to all information sources. That's not the same as saying I believe everything I read and whilst the journo might have got confused between POLB and Imutex it suggests a) that CF needs to make his communications more clear and distinctive when talking to non specialists, and that b) the financial journo's current assessment of Poolbeg as a risky investment is not necessarily wrong. As with all things related to CF these days, and reviving an old US burger ad and Presidential campaign slogan, "Where's the beef?"